Cell therapy is called
The third pillar of future medicine,
Because safety and effectiveness are placed on high hopes,
But there are also many challenges.
How is cell therapy leading the future?
How will pharmaceutical companies lay out in the future?
How does the commercialization factor work?
In response to these problems, on October 27, under the guidance of Zhuhai High-tech Zone Investment Promotion Center, Guangdong Medical Valley and Zhongchuang Industry Research Institute, the "Cell Therapy and Targeted Drug Innovation transformation - 150 Guangdong Medical Valley Open Day Top 50 Selection Shenzhen Special Session" was held in Shenzhen, and CUHK Venture Capital, International Medical Industry Innovation Center and Southern Medical Network strongly supported the event.
The forum invited industry experts, innovative technology entrepreneurs, well-known investors and other industry elites to attend, focusing on the innovation and transformation of cell therapy and targeted drugs.
Zheng Yao, Deputy Director of the Commerce Bureau of Zhuhai High-tech Zone, Selina Yuan, Commercial Representative of the Australian Trade and Investment Commission, Huang Xi, Academic Director of the Fifth Affiliated Hospital of Sun Yat-sen University and Chairman of Qinyuan Regenerative Medicine, Fu Jun, Professor of School of Materials Science and Engineering of Sun Yat-sen University, Professor Zhou Shoujun of Shenzhen Advanced Institute of Chinese Science, Zhong Jing, Managing Director of Guoke Jiahe, Zhang Zhixing, Director of Oriental Fuhai Investment, Yang Yi, General Manager of Zhuhai Hi-Tech Venture Investment Business Department, Wei Ting, Executive Director of Cornerstone Capital, Zhang Jishuai, Founder and Chief Technology Officer of Prinkin, Wang Yihan, founder & CEO of Tagiri, Xu Xiaosong, chairman of Baifu Life, Liu Shumin, founder of Kangyuan Jiuyuan, Huo Qing, CCO of Kangti Life, and Xie Jiasheng, CEO of Guangdong Medical Valley, attended the event.
In addition, there were also Zhuhai High-tech Zone Investment Promotion Center, Shenzhen Advanced Institute of Science and Technology, Zhongchuang Industry Research Institute, Shuncheng Capital, Huiyuan Technology, ZTE Weixiantong, Century Changhe, Wuming Investment, Rongzhong Capital, Gaoxin Investment, Shenxue Capital and other institutions.
Zheng Yao, deputy director of the Commerce Bureau of Zhuhai High-tech Zone, said in his speech that Zhuhai High-tech Zone has initially formed a development model of "resource complementarity + win-win cooperation" and "Shenzhen headquarters (window) + Shenzhen cooperative research and development and production", comprehensively docking Shenzhen industry and supporting the transformation of scientific and technological achievements into Zhuhai High-tech Zone.
Zheng Yao, deputy director of the Commerce Bureau of Zhuhai High-tech Zone
Guangdong Medical Valley Executive President Xie Jiasheng said that on October 8, Guangdong Medical Valley office in Shenzhen was officially opened, in the future, there will be more and more high-quality industry exchange activities held in Shenzhen, Guangdong Medical Valley will also focus on creating a new benchmark for the development of the biomedical industry, accelerate the communication of innovative elements of the biomedical industry in Guangzhou, Zhuhai and Shenzhen, and help the coordinated development of the biomedical industry in the Guangdong-Hong Kong-Macao Greater Bay Area.
Guangdong Medical Valley EXECUTIVE PRESIDENT Xie Jiasheng
Lu Xiaohui, research director of Zhongchuang Industry Research Institute, gave a speech on the fourth Guangdong-Hong Kong-Macao Greater Bay Area Top 50 Biotechnology Enterprises Selection at the event, the last batch of application deadline is October 31, only a few days from the enterprise registration deadline, the registration official website: http://www.biotech-top50.com/, sincerely invite outstanding biotechnology enterprises in the Greater Bay Area to register for election, jointly record the current situation of the biotechnology industry in the Guangdong-Hong Kong-Macao Greater Bay Area, and gain insight into the future development trend!
Lu Xiaohui, research director of Zhongchuang Industry Research Institute
Zhang Jishuai, founder and chief technology officer of Shenzhen Prijin, shared the research and development and industrialization of immune cell drugs, he pointed out that cell and gene therapy will become the mainstream of future therapies, and factors such as effective safety, reduced price, and convenient use will make immune cell drug technology industrialized.
Zhang Jishuai, founder and chief technology officer of Shenzhen Prijin
The biomedical industry has good growth, considerable prospects for future development, with high technology, high investment, high risk, long cycle and other characteristics, how to find and evaluate the dark horse of the biomedical and pharmaceutical industry?
Zhong Jing, managing director of Guokejiahe, said that under the epidemic, fund fund investment ushered in a new wave of climax, biopharmaceuticals, health technology, diagnostic tools and medical devices are still the focus, while biotechnology is mainly used in treatment, diagnosis, agriculture and other technology platforms, its indications, platform technology, team are important factors in biomedical investment, and pointed out that under the great development of biomedicine, some small and beautiful projects may have a large development track.
Guo Kejia and Managing Director Zhong Jing
Subsequently, a roundtable dialogue with the theme of "Building a Cell Therapy and Targeted Drug Industry Innovation Ecosystem" was launched on the spot, hosted by Xie Jiasheng, EXECUTIVE President of Guangdong Medical Valley, and invited Huang Xi, Academic Director of the Fifth Affiliated Hospital of Sun Yat-sen University and Chairman of Qinyuan Regenerative Medicine, Zhang Zhixing, Investment Director of Oriental Fuhai, Wang Yihan, Founder & CEO of Tagiri, Xu Xiaosong, Chairman of Baifu Life, Liu Shumin, Founder of Kangyuan Jiuyuan, Huo Qing, CCO of Kangtian Life, and other guests to explore new opportunities in the cell therapy and targeted drug industry.
Round table dialogue
In the course of the roundtable dialogue,
Academic Director of the Fifth Affiliated Hospital of Sun Yat-sen University,
Professor Huang Xi, Chairman of Qinyuan Regenerative Medicine, pointed out that
Innovative ideas for cell therapy and targeted drug development
It will bring new life to patients.
Huang Xi, Chairman of Qinyuan Regenerative Medicine
The guests launched a wonderful collision of ideas around the original target cell therapy, the transformation of cutting-edge research achievements, industrial investment layout and future development trends, etc., and representatives of many institutions said that more attention should be paid to cell therapy and targeted drug innovation in the Guangdong-Hong Kong-Macao Greater Bay Area, and related enterprises and capital should cooperate to develop and create an industrial ecosystem.
At present, the Guangdong-Hong Kong-Macao Greater Bay Area is constantly promoting the construction of industrial infrastructure, shenzhen has a good external environment, a solid industrial foundation, a strong ability to innovate, and continuously accumulate strength for the better development of the biomedical industry.
Communicate freely
Guangdong Medical Valley open day
One is provided for the industry
High-quality, high-end communication platform,
future
Guangdong Medical Valley will further enhance the level of innovative services,
Gather the innovative elements of high-end medical industry,
Constantly improve the industrial ecological service system,
Supporting all regions of the Guangdong-Hong Kong-Macao Greater Bay
The biomedical industry develops in synergy.
Source: Bureau of Commerce of High-tech Zone, Guangdong Medical Valley